Trial Profile
Predictive markers of joint damage in children with systemic-onset juvenile idiopathic arthritis receiving long-term treatment with tocilizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 14 Dec 2015 New trial record